Production (Stage)
Alto Neuroscience, Inc.
ANRO
$3.03
$0.103.41%
NYSE
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 22.88M | 21.61M | 17.54M | 13.46M | 10.36M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 69.90M | 68.61M | 63.38M | 54.21M | 44.99M |
Operating Income | -69.90M | -68.61M | -63.38M | -54.21M | -44.99M |
Income Before Tax | -63.18M | -61.43M | -57.45M | -49.81M | -42.44M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -63.18 | -61.43 | -57.45 | -49.81 | -42.44 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -63.18M | -61.43M | -57.45M | -49.81M | -42.44M |
EBIT | -69.90M | -68.61M | -63.38M | -54.21M | -44.99M |
EBITDA | -69.32M | -68.11M | -62.93M | -53.83M | -44.61M |
EPS Basic | -2.35 | -2.55 | -4.95 | -6.77 | -8.51 |
Normalized Basic EPS | -1.45 | -1.59 | -3.10 | -4.23 | -5.32 |
EPS Diluted | -2.35 | -2.55 | -4.95 | -6.77 | -8.51 |
Normalized Diluted EPS | -1.45 | -1.59 | -3.10 | -4.23 | -5.32 |
Average Basic Shares Outstanding | 107.70M | 98.25M | 75.25M | 52.03M | 28.83M |
Average Diluted Shares Outstanding | 107.70M | 98.25M | 75.25M | 52.03M | 28.83M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |